IRCT20200406046968N3招募中2 期
effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital
Zist Daru Danesh Company0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •respiratory rate> 24 / min
- •pao2 / Fio2< 300
排除标准
- •history of Sensitivity to interferon-beta 1 compounds (zifron)
- •History of advanced liver disease and liver enzymes three times normal
- •history of severe depression or suicidal thought
研究者
相似试验
进行中（未招募）
不适用
The effect of interferon beta-1a treatment on adaptability of the brain in patients with MSMultiple sclerosisMedDRA version: 14.0Level: PTClassification code 10004504Term: Beta interferon therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2011-003570-89-NLVU University Medical Center
已完成
3 期
Comparison of Interferon-beta-1a and Dexamethasone on hospitalized patients with Covid-19.IRCT20150622022869N9Yasouj University of Medical Sciences176
招募中
2 期
Interferon ß in treatment of COVID-19IRCT20100228003449N27Tehran University of Medical Sciences30
已完成
3 期
Efficacy and safety of peginterferon beta-1a (CinnaGen) in relapsing-remitting multiple sclerosis patients.Multiple sclerosis.Multiple sclerosisIRCT201612306135N8CinnaGen Pharmaceutical Company168
已完成
3 期
Comparison of Ziferon and Betaferon in multiple sclerosis managementMultiple Sclerosis (MS).Demyelinating diseases of the central nervous systemIRCT138806102397N1Medical Vice chancellor for research, Tehran University of Science50